Virus Diseases Clinical Trial
Official title:
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age
Human Parainfluenza Virus Type 1 (HPIV1) is a leading cause of viral respiratory infections in children, the elderly, and those with compromised immune systems. HPIV1 is also the leading cause of viral croup in children under 6 years old. The purpose of this study is to determine the safety of and immune response to a HPIV1 vaccine, rHPIVI1 84/del170/942A, in 2 groups of adults and then in children who have been previously exposed to HPIV1. Once the safety of this vaccine has been established in these groups, an additional 2 groups of infants and children who have not been previously exposed to HPIV1 will be vaccinated. Naïve infants and children are the most vulnerable to naturally circulating HPIV1 and are the target population of this vaccine.
HPIV1 infection can result in severe respiratory illness that often leads to the
hospitalization of infants and young children. HPIV1 is responsible for approximately 6% of
all pediatric hospitalizations for respiratory tract diseases and is a main cause of severe
lower respiratory tract diseases, including pneumonia and bronchiolitis in children less
than 6 years old. The purpose of this study is to determine the safety of and immune
response to a HPIV1 vaccine, rHPIVI1 84/del170/942A, in 5 main volunteer group: first in
adults (group 1 and 2), and then in seropositive children (group 3). The last 2 groups will
be seronegative infants and children that are split into 2 dosing groups; one group of
seronegative infants and children will receive a lower dose of vaccine (group 4) and a
second group of seronegative infants and children (group 5) will receive a higher dose of
vaccine. This study will last approximately 8 weeks per group. Additional information about
each of the groups is as follows:
Groups 1 and 2 will consist of 35 adults total, 18 to 49 years of age. These groups will
receive one immunization with rHPIV1 84/del170/942A at study entry. Immunization will be
given as nose drops. Study visits will occur on Days 3, 4, 5, 6, 7, 10, and 28. Medical
history, vital signs, clinical assessment, and nasal wash will occur at most visits. Blood
and urine tests will occur at selected visits. A urine pregnancy test will occur for females
at study entry. Follow-up phone reports will also be required on Day 56.
Enrollment into Group 3 will begin only after safety data from Groups 1 and 2 are evaluated.
Group 3 will consist of 15 seropositive children, 15 to 59 months of age. This group will
receive either one immunization of rHPIV1 84/del170/942A or placebo at study entry.
Immunization will be given as nose drops. Study visits will occur on Days 3, 4, 5, 6, 7, 10,
and 28. Medical history, vital signs, clinical assessment, and nasal wash will occur at most
visits. Blood and urine tests will occur at selected visits. Parents will be required to
submit reports over the phone throughout the study. These reports will include the temporal
temperature from the previous day.
Enrollment into Group 4 will begin only after safety data from Group 3 are evaluated. Group
4 will consist of 21-30 seronegative infants and children, 6 to 59 months of age. This group
will receive either one immunization of rHPIV1 84/del170/942A or placebo at study entry.
Immunization will be given as nose drops. Study visits will occur on Days 3, 5, 7, 10, 12,
14, 17, 19, 21, 28, and 56. Medical history, vital signs, clinical assessment, and nasal
wash will occur at most visits. Blood tests will occur at selected visits. Parents will be
required to submit reports over the phone throughout the study. These reports will include
the temporal temperature from the previous day.
Enrollment into Group 5 will begin only after safety data from Group 4 are evaluated. Group
5 will consist of 21-30 seronegative infants and children 6 to 59 months of age. This group
will receive either one immunization of rHPIV1 84/del170/942A or placebo at study entry. The
immunization will be given as nose drops. The vaccine dosage that participants receive in
Group 5 will be greater than the dose in Group 4. Study visits will occur on Days 3, 5, 7,
10, 12, 14, 17, 19, 21, 28, and 56. Medical history, vital signs, clinical assessment, and
nasal wash will occur at most visits. Blood tests will occur at selected visits. Parents
will be required to submit reports over the phone throughout the study. These reports will
include the temporal temperature from the previous day.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
Completed |
NCT00984945 -
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT00734175 -
Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine
|
Phase 1 | |
Completed |
NCT00516035 -
Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults
|
Phase 1 | |
Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
Completed |
NCT03739112 -
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
|
Phase 3 | |
Recruiting |
NCT06113757 -
Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease
|
N/A | |
Completed |
NCT01991587 -
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT03294135 -
The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
|
Phase 4 | |
Active, not recruiting |
NCT02545517 -
A Clinical Study to Evaluate Immune Responses to Rabies Vaccine in Adults Who Received Different Primary Rabies Vaccination Regimens
|
Phase 3 | |
Active, not recruiting |
NCT05619770 -
Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects
|
Phase 1 | |
Not yet recruiting |
NCT01289301 -
Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant
|
Phase 4 | |
Active, not recruiting |
NCT01055990 -
Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients
|
Phase 2 | |
Completed |
NCT00980447 -
Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults
|
Phase 2 | |
Completed |
NCT01842997 -
Safety of H1N1 Influenza Vaccination in Pregnant Women
|
Phase 4 | |
Completed |
NCT00380237 -
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)
|
Phase 1 | |
Completed |
NCT00219453 -
Pilot Safety Study to Determine the Ability of the Protector Cap Jet Injector to Prevent Cross-Contamination
|
Phase 1 | |
Completed |
NCT02548078 -
A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children
|
Phase 2 |